State of Wisconsin Investment Board decreased its holdings in Celgene Co. (NASDAQ:CELG) by 6.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 757,406 shares of the biopharmaceutical company’s stock after selling 48,286 shares during the quarter. State of Wisconsin Investment Board owned 0.11% of Celgene worth $60,153,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Virginia Retirement Systems ET AL lifted its position in Celgene by 32.5% in the 2nd quarter. Virginia Retirement Systems ET AL now owns 328,500 shares of the biopharmaceutical company’s stock valued at $26,089,000 after acquiring an additional 80,500 shares in the last quarter. Price Capital Management Inc. bought a new position in Celgene in the 2nd quarter valued at about $717,000. Sompo Japan Nipponkoa Asset Management CO. LTD. bought a new position in Celgene in the 2nd quarter valued at about $2,164,000. Isthmus Partners LLC lifted its position in Celgene by 3.7% in the 2nd quarter. Isthmus Partners LLC now owns 56,721 shares of the biopharmaceutical company’s stock valued at $4,505,000 after acquiring an additional 1,999 shares in the last quarter. Finally, Sigma Planning Corp lifted its position in Celgene by 32.2% in the 2nd quarter. Sigma Planning Corp now owns 16,352 shares of the biopharmaceutical company’s stock valued at $1,299,000 after acquiring an additional 3,984 shares in the last quarter. 77.71% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director James J. Loughlin sold 17,750 shares of Celgene stock in a transaction that occurred on Monday, June 4th. The shares were sold at an average price of $78.96, for a total value of $1,401,540.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gilla Kaplan sold 27,750 shares of Celgene stock in a transaction that occurred on Friday, May 18th. The shares were sold at an average price of $78.66, for a total transaction of $2,182,815.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 58,500 shares of company stock valued at $4,608,365. 0.39% of the stock is currently owned by company insiders.

Several equities analysts have commented on CELG shares. Credit Suisse Group set a $129.00 target price on shares of Celgene and gave the stock a “buy” rating in a research report on Tuesday, April 17th. Zacks Investment Research raised shares of Celgene from a “sell” rating to a “hold” rating in a research report on Thursday, April 19th. Evercore ISI reissued a “buy” rating on shares of Celgene in a research report on Monday, April 30th. ValuEngine cut shares of Celgene from a “sell” rating to a “strong sell” rating in a research report on Wednesday, May 2nd. Finally, Cantor Fitzgerald set a $112.00 target price on shares of Celgene and gave the stock a “hold” rating in a research report on Saturday, May 5th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twenty have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $121.85.

Shares of CELG stock opened at $91.21 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.52 and a debt-to-equity ratio of 5.76. Celgene Co. has a 12-month low of $74.13 and a 12-month high of $147.17. The company has a market cap of $64.65 billion, a PE ratio of 12.91, a P/E/G ratio of 0.57 and a beta of 1.32.

Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.16 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.05. Celgene had a net margin of 19.81% and a return on equity of 87.28%. The company had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.70 billion. During the same quarter last year, the business posted $1.82 EPS. Celgene’s quarterly revenue was up 16.6% compared to the same quarter last year. equities analysts forecast that Celgene Co. will post 7.64 earnings per share for the current fiscal year.

Celgene declared that its board has authorized a share repurchase plan on Thursday, May 24th that allows the company to repurchase $3.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to purchase up to 5.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its shares are undervalued.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: Investing in Dividend Stocks

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.